vs
HERITAGE FINANCIAL CORP（HFWA）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是HERITAGE FINANCIAL CORP的1.9倍（$127.1M vs $66.3M），再鼎医药同比增速更快（17.1% vs 16.3%），HERITAGE FINANCIAL CORP自由现金流更多（$85.7M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 16.8%）
总部位于美国华盛顿州的区域性金融控股公司，面向太平洋西北地区的当地社群提供服务，核心业务涵盖商业与零售银行服务，包含存款产品、中小企业贷款、住房抵押贷款、个人信贷及财富管理解决方案，核心客群为中小微企业及个人客户。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
HFWA vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.9倍
$66.3M
营收增速更快
ZLAB
高出0.8%
16.3%
自由现金流更多
HFWA
多$112.4M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
16.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $66.3M | $127.1M |
| 净利润 | $22.2M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 38.7% | -54.6% |
| 净利率 | 33.5% | — |
| 营收同比 | 16.3% | 17.1% |
| 净利润同比 | 86.4% | — |
| 每股收益（稀释后） | $0.65 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HFWAZLAB
| Q4 25 | $66.3M | $127.1M | ||
| Q3 25 | $65.7M | $115.4M | ||
| Q2 25 | $56.5M | $109.1M | ||
| Q1 25 | $57.6M | $105.7M | ||
| Q4 24 | $57.1M | $108.5M | ||
| Q3 24 | $54.8M | $101.8M | ||
| Q2 24 | $56.4M | $100.1M | ||
| Q1 24 | $48.6M | $87.1M |
净利润HFWAZLAB
| Q4 25 | $22.2M | — | ||
| Q3 25 | $19.2M | $-36.0M | ||
| Q2 25 | $12.2M | $-40.7M | ||
| Q1 25 | $13.9M | $-48.4M | ||
| Q4 24 | $11.9M | — | ||
| Q3 24 | $11.4M | $-41.7M | ||
| Q2 24 | $14.2M | $-80.3M | ||
| Q1 24 | $5.7M | $-53.5M |
毛利率HFWAZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率HFWAZLAB
| Q4 25 | 38.7% | -54.6% | ||
| Q3 25 | 34.0% | -42.3% | ||
| Q2 25 | 25.6% | -50.3% | ||
| Q1 25 | 28.1% | -53.3% | ||
| Q4 24 | 28.6% | -62.6% | ||
| Q3 24 | 23.8% | -66.6% | ||
| Q2 24 | 28.4% | -76.0% | ||
| Q1 24 | 14.1% | -80.7% |
净利率HFWAZLAB
| Q4 25 | 33.5% | — | ||
| Q3 25 | 29.2% | -31.2% | ||
| Q2 25 | 21.6% | -37.3% | ||
| Q1 25 | 24.2% | -45.8% | ||
| Q4 24 | 20.9% | — | ||
| Q3 24 | 20.8% | -40.9% | ||
| Q2 24 | 25.1% | -80.2% | ||
| Q1 24 | 11.8% | -61.4% |
每股收益（稀释后）HFWAZLAB
| Q4 25 | $0.65 | $-0.05 | ||
| Q3 25 | $0.55 | $-0.03 | ||
| Q2 25 | $0.36 | $-0.04 | ||
| Q1 25 | $0.40 | $-0.04 | ||
| Q4 24 | $0.34 | $-0.09 | ||
| Q3 24 | $0.33 | $-0.04 | ||
| Q2 24 | $0.41 | $-0.08 | ||
| Q1 24 | $0.16 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $233.1M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $921.5M | $715.5M |
| 总资产 | $7.0B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HFWAZLAB
| Q4 25 | $233.1M | $689.6M | ||
| Q3 25 | $245.5M | $717.2M | ||
| Q2 25 | $254.1M | $732.2M | ||
| Q1 25 | $248.7M | $757.3M | ||
| Q4 24 | $117.1M | $779.7M | ||
| Q3 24 | $175.6M | $616.1M | ||
| Q2 24 | $113.8M | $630.0M | ||
| Q1 24 | $189.6M | $650.8M |
股东权益HFWAZLAB
| Q4 25 | $921.5M | $715.5M | ||
| Q3 25 | $904.1M | $759.9M | ||
| Q2 25 | $888.2M | $791.7M | ||
| Q1 25 | $881.5M | $810.8M | ||
| Q4 24 | $863.5M | $840.9M | ||
| Q3 24 | $874.5M | $667.7M | ||
| Q2 24 | $850.5M | $704.2M | ||
| Q1 24 | $847.6M | $762.2M |
总资产HFWAZLAB
| Q4 25 | $7.0B | $1.2B | ||
| Q3 25 | $7.0B | $1.2B | ||
| Q2 25 | $7.1B | $1.2B | ||
| Q1 25 | $7.1B | $1.2B | ||
| Q4 24 | $7.1B | $1.2B | ||
| Q3 24 | $7.2B | $985.3M | ||
| Q2 24 | $7.1B | $987.4M | ||
| Q1 24 | $7.1B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $94.8M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $85.7M | $-26.7M |
| 自由现金流率自由现金流/营收 | 129.1% | -21.0% |
| 资本支出强度资本支出/营收 | 13.8% | 0.5% |
| 现金转化率经营现金流/净利润 | 4.26× | — |
| 过去12个月自由现金流最近4个季度 | $149.0M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流HFWAZLAB
| Q4 25 | $94.8M | $-26.0M | ||
| Q3 25 | $25.1M | $-32.0M | ||
| Q2 25 | $22.5M | $-31.0M | ||
| Q1 25 | $19.3M | $-61.7M | ||
| Q4 24 | $64.5M | $-55.8M | ||
| Q3 24 | $24.2M | $-26.8M | ||
| Q2 24 | $6.8M | $-42.2M | ||
| Q1 24 | $12.9M | $-90.1M |
自由现金流HFWAZLAB
| Q4 25 | $85.7M | $-26.7M | ||
| Q3 25 | $24.4M | $-35.0M | ||
| Q2 25 | $20.9M | $-33.9M | ||
| Q1 25 | $18.1M | $-63.2M | ||
| Q4 24 | $61.0M | $-58.4M | ||
| Q3 24 | $23.2M | $-28.2M | ||
| Q2 24 | $6.0M | $-42.9M | ||
| Q1 24 | $12.0M | $-91.1M |
自由现金流率HFWAZLAB
| Q4 25 | 129.1% | -21.0% | ||
| Q3 25 | 37.1% | -30.4% | ||
| Q2 25 | 37.0% | -31.1% | ||
| Q1 25 | 31.4% | -59.9% | ||
| Q4 24 | 107.0% | -53.8% | ||
| Q3 24 | 42.4% | -27.7% | ||
| Q2 24 | 10.6% | -42.9% | ||
| Q1 24 | 24.7% | -104.5% |
资本支出强度HFWAZLAB
| Q4 25 | 13.8% | 0.5% | ||
| Q3 25 | 1.0% | 2.6% | ||
| Q2 25 | 2.8% | 2.6% | ||
| Q1 25 | 2.0% | 1.5% | ||
| Q4 24 | 6.1% | 2.4% | ||
| Q3 24 | 1.7% | 1.3% | ||
| Q2 24 | 1.5% | 0.7% | ||
| Q1 24 | 1.8% | 1.1% |
现金转化率HFWAZLAB
| Q4 25 | 4.26× | — | ||
| Q3 25 | 1.31× | — | ||
| Q2 25 | 1.84× | — | ||
| Q1 25 | 1.38× | — | ||
| Q4 24 | 5.41× | — | ||
| Q3 24 | 2.12× | — | ||
| Q2 24 | 0.48× | — | ||
| Q1 24 | 2.24× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HFWA
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
